Chengdu Shibeikang Biopharmaceutical Technology

Chengdu Shibeikang Biopharmaceutical Technology (SBK) is a research-driven biotechnology company founded in 2015 and headquartered in Chengdu, China. The company focuses on the discovery and development of differentiated innovative drugs for cardiovascular, cerebrovascular, and respiratory diseases. SBK utilizes its proprietary A-MetaForge™ AI-powered metabolic differentiation platform to optimize the metabolic profiles of drug candidates, aiming to improve clinical success rates. Its lead innovative asset, Becondogrel (SBK002), is a next-generation antiplatelet agent currently under NDA review in China for the prevention of atherothrombotic events. The company's pipeline also includes SBK001, a first-in-class mucolytic in Phase II, and SBK013, a Factor XI inhibitor in Phase I, alongside a commercialized chloral hydrate syrup for sedation.